In Brief: International Murex
This article was originally published in The Gray Sheet
Executive Summary
International Murex: Launches five new rapid diagnostic test kits to U.S. clinical reference and hospital laboratories. The company says that the five products, recently cleared by FDA, include kits to "assist in the detection of antibodies to: infectious mononucleosis, group A streptococcus [and] rheumatoid arthritis (two tests)," as well as a test to detect C-reactive protein. The kits, which can provide both qualitative and semiqualitative results, "require no instrumentation," provide results "between 2 and 10 minutes" and "are all equipped with disposable slides that minimize the risk of contamination." The combined market for the new test kits is about $20 mil., Murex estimates...